Current NICE/CDF drug approvals for CLL
| NICE / CDF approvals for novel therapies in CLL as of October 2021
(England) |
|
Front-line |
Options |
| No TP53 mutation or deletion | FCR/BR unsuitable
• Acalabrutinib • Venetoclax + Obinutuzumab FCR/BR suitable • Venetoclax + Obinutuzumab (CDF) |
| TP53 mutated/deleted | • Acalabrutinib
• Ibrutinib • Idelalisib + Rituximab (only if other therapies not suitable) • Venetoclax + Obinutuzumab |
Lymphoid leukaemia – NICE Pathways
| NICE / CDF approvals for novel therapies in CLL as of October 2021
(England) |
|
Relapse |
Options |
| No TP53 mutation or deletion | Prior Venetoclax and/or chemoimmunotherapy
• Acalabrutinib • Ibrutinib Prior BTKi and/or chemoimmunotherapy • Venetoclax + Rituximab Prior BTKi and chemoimmunotherapy • Venetoclax monotherapy (CDF) |
| TP53 mutated/deleted | Prior BTKi therapy
• Venetoclax monotherapy (CDF) |
| All patients for relapse within 24 months | Idelalisib + Rituximab |
Lymphoid leukaemia – NICE Pathways
- NICE: National Institute of Clinical Excellence
- CDF: Cancer Drugs Fund
- FCR: Fludarabine, Cyclophosphamide, Rituximab
- BR: Bendamustine, Rituximab
- BTKi: Bruton’s Tyrosine Kinase inhibitor (Acalabrutinib, Ibrutinib)